GlobeNewswire Inc.··Inflarx N.V.InflaRx Faces Nasdaq Delisting Risk After Stock Falls Below $1 Threshold
$IFRX received Nasdaq deficiency notice for failing $1 minimum bid price for 30 consecutive days. Company has until September 2026 to regain compliance or face delisting.
IFRXbiopharmaceuticalNasdaq listing compliance